SV2A
Synaptic vesicle glycoprotein 2A
As of the edition of 20 October 2026, SV2A (synaptic vesicle glycoprotein 2A, UniProt Q7L0J3) has 6 drugs tested at it and 9 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q7L0J3
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 23
- Disease areas
- Nervous system; Mental health; Cancer; Inherited and neonatal; Chemically induced; Heart and blood vessels; Injuries; Blood and lymph
- Registered trials of its drugs
- 274
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Stopped | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Levetiracetam | Marketed | Phase 4 | none listed |
| Brivaracetam | Marketed | Phase 3 | Ended 2026 |
| Padsevonil | Stopped | Phase 3 | none listed |
| Seletracetam | Stopped | Phase 3 | none listed |
| ABBV-552 | Active | Phase 2 | none listed |
| Plosaracetam | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 6 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Aché Laboratórios Farmacêuticos | Route B |
| Adium | Route B |
| Syndesi Therapeutics | Route A |
The other 6 companies at SV2A
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at SV2A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.